Recent Updates
Recently added Catalysts

PF-07264660 single ascending dose

Phase 1

Healthy | Small molecule | Other |Pfizer, Inc.|Last Updated: Jun 6, 2024

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment59

FDA Designations

No designations recorded

Clinical trial landscape

PF-07264660 single ascending dose · 1 trial · 1 indication

Phase 1 1
NCT05496738A Preliminary Study to Evaluate PF-07264660 in Healthy ParticipantsHealthy
COMPLETED59 Analytics
PHASE1COMPLETED
A Preliminary Study to Evaluate PF-07264660 in Healthy Participants
Healthy
NCT0549673859
Unlock trial analytics

Study Endpoints

Primary Endpoints

Number of participants with treatment emergent treatment related adverse events (AE's)
Baseline up to approximately 1.5 years

To evaluate the safety and tolerability of PF 07264660, following single and multiple doses in healthy adults

Number of participants with treatment emergent treatment-related serious adverse events (SAE's)
Baseline up to approximately 1.5 years

To evaluate the safety and tolerability of PF 07264660, following single and multiple doses in healthy adults

Number of participants with change from baseline in blood pressure
Baseline up to approximately 1.5 years

Identify systolic and diastolic readings that are outside the normal range. The number and percentage of participants who experienced significant blood pressure change from baseline will be summarized

Number of participants with change from baseline in pulse rate
Baseline up to approximately 1.5 years

Identify pulse rate readings that are outside the normal range. The number and percentage of participants who experienced significant pulse rate change from baseline will be summarized

Number of participants with change from baseline in temperature
Baseline up to approximately 1.5 years

Identify temperature readings that are outside the normal range. The number and percentage of participants who experienced significant temperature change from baseline will be summarized

Number of participants with change from baseline in clinical laboratory values
Baseline up to approximately 1.5 years

Identify laboratory abnormalities from baseline will be summarized

Number of participants with change from baseline in heart rate
Baseline up to approximately 1.5 years

Determine the effect of the drug on heart rate The number and percentage of participants who experienced heart rate changes will be summarized

Number of participants with change from baseline in QT interval
Baseline up to approximately 1.5 years

Determine the effect of the drug on QT interval. The number and percentage of participants who experienced QT interval changes will be summarized

Number of participants with change from baseline in corrected QT interval
Baseline up to approximately 1.5 years

Determine the effect of the drug on corrected QT interval. The number and percentage of participants who experienced corrected QT interval changes will be summarized

Number of participants with change from baseline in PR interval
Baseline up to approximately 1.5 years

Determine the effect of the drug on PR interval. The number and percentage of participants who experienced PR interval changes will be summarized

Number of participants with change from baseline in QRS interval
Baseline up to approximately 1.5 years

Determine the effect of the drug on QRS interval. The number and percentage of participants who experienced QRS interval changes will be summarized

Secondary Endpoints

Number of participants with change from baseline in area under the concentration versus time curve from time zero to the last quantifiable time point (AUClast) of single ascending doses of PF-07264660
Baseline up to approximately 1.5 years
Number of participants with change from baseline in maximum plasma concentration (Cmax) of PF-07264660 after a single dose
Baseline up to approximately 1.5 years
Number of participants with change from baseline in maximum plasma concentration (Cmax) of PF-07264660 after multiple doses
Baseline up to approximately 1.5 years
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
PF-07264660 intravenous single ascending doseEXPERIMENTALPF-07264660 will be administered intravenously
PF-07264660 subcutaneous multiple ascending doseEXPERIMENTALPF-07264660 will be administered subcutaneously
Intravenous placeboPLACEBO_COMPARATORPlacebo will be administered intravenously
Subcutaneous PlaceboPLACEBO_COMPARATORPlacebo will be administered subcutaneously

Interventions

NameTypeDescription
PF-07264660 intravenous single ascending doseDRUGPF-07264660 will be administered intravenously in single ascending doses
PF-07264660 subcutaneous multiple ascending doseDRUGPF-07264660 will be administered subcutaneously in multiple ascending doses
Intravenous placeboOTHERPlacebo will be administered intravenously in single ascending doses
subcutaneous placeboOTHERPlacebo will be administered subcutaneously in multiple ascending doses
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 65 Years
SexALL
Healthy VolunteersYes
Study Sites6

Inclusion Criteria: * Healthy volunteer male and female participants between 18 to 65 years of age * Body Mass Index (BMI) of 17.5 to 32 kg/m2; and a total body weight \>50 kg (110 lb) Exclusion Criteria: * Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, ...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about PF-07264660 single ascending dose

What is PF-07264660 used for?

PF-07264660 is an investigational small molecule being studied in healthy participants. It is currently in Phase 1 clinical development, with a completed trial evaluating its effects in healthy volunteers. The drug is being developed by Pfizer, Inc. and is not yet approved for any medical use.

Who makes PF-07264660?

PF-07264660 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 1 clinical development, with one completed trial in healthy participants.

What phase is PF-07264660 in?

PF-07264660 is in Phase 1 clinical development. A Phase 1 study, NCT05496738, has been completed, evaluating the drug in healthy participants. The drug is investigational and has not been approved by regulatory authorities.

What clinical trials is PF-07264660 in?

PF-07264660 has one clinical trial, NCT05496738, titled "A Preliminary Study to Evaluate PF-07264660 in Healthy Participants." This Phase 1 study was completed in the United States, enrolled 59 participants, and was randomized, double-blind, and placebo-controlled.

Is PF-07264660 FDA approved?

PF-07264660 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. A completed Phase 1 trial, NCT05496738, evaluated the drug in healthy participants, but it remains in clinical development and has not been approved for any use.